NAYA Biosciences (NAYA) 10-Q 15 May 20 2020 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 15, 2020
Document Information Line Items
Entity Registrant Name	INVO Bioscience, Inc.,
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		157,774,336
Amendment Flag	false
Entity Central Index Key	0001417926
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Interactive Data Current	Yes

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Cash	$ 350,000	$ 1,238,585
Accounts receivable net	3,699	7,558
Inventory, net	162,283	101,387
Prepaid expense and other current assets	173,235	195,910
Total current assets	689,217	1,543,440
Property and equipment, net	111,055	93,055
Capitalized patents, net	6,782	7,234
Lease right of use, net	96,354	101,883
Trademarks	54,474	49,867
Total other assets	157,610	158,984
Total assets	957,882	1,795,479
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
Accounts payable and accrued liabilities, including related parties	294,739	371,530
Accrued compensation	487,161	393,017
Deferred revenue	714,286	714,286
Current portion of lease liability	21,704	21,365
Convertible notes, net of discount	371,695	0
Convertible notes, net of discount – related party	33,152	0
Income taxes payable	912	912
Total current liabilities	1,923,649	1,501,110
Commitments and contingencies
Lease liability, net of current portion	75,992	81,494
Deferred revenue	3,392,857	3,571,429
Convertible notes, net of discount	0	325,784
Convertible notes, net of discount – related party	0	28,824
Deferred tax liability	433	433
Total liabilities	5,392,931	5,509,074
Stockholder's deficiency
Preferred Stock, $.0001 par value; 100,000,000 shares authorized; No shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively	0	0
Common Stock, $.0001 par value; 200,000,000 shares authorized; 157,774,336 and 156,316,112 issued and outstanding as of March 31, 2020 and December 31, 2019, respectively	15,777	15,631
Additional paid-in capital	20,882,332	20,159,540
Accumulated deficit	(25,333,158)	(23,888,766)
Total stockholder's deficiency	(4,435,049)	(3,713,595)
Total liabilities and stockholders' deficiency	$ 957,882	$ 1,795,479

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Preferred Stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized	100,000,000	100,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common Stock, shares authorized	200,000,000	200,000,000
Common Stock, shares issued	157,774,336	156,316,112
Common Stock, shares outstanding	157,774,336	156,316,112

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue	$ 258,571	$ 189,432
Cost of goods sold	29,994	10,978
Gross margin	228,577	178,454
Selling, general and administrative expenses	1,595,046	527,565
Research and developments costs	30,050	0
Total operating expenses	1,625,096	527,565
Loss from operations	(1,396,519)	(349,111)
Other (income) expense:
Interest expense	47,873	109,459
Total other ( income) expenses	47,873	109,459
Loss before income taxes	(1,444,392)	(458,570)
Provision for income taxes	0	0
Net loss	$ (1,444,392)	$ (458,570)
Basic net loss per weighted average shares of common stock (in Dollars per share)	$ (0.01)	$ 0
Diluted net loss per weighted average shares of common stock (in Dollars per share)	$ (0.01)	$ 0
Basic weighted average number of shares of common stock (in Shares)	157,375,918	154,102,856
Diluted weighted average number of shares of common stock (in Shares)	157,375,918	154,102,856
Product Revenue [Member]
Revenue	$ 80,000	$ 10,860
License [Member]
Revenue	$ 178,571	$ 178,572

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY DEFICIENCY - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2018	$ 15,429	$ 18,981,570	$ (21,721,222)	$ (2,724,223)
Balance (in Shares) at Dec. 31, 2018	154,292,497
Common stock issues for settlement	$ 6	26,594		26,600
Common stock issues for settlement (in Shares)	60,000
Conversion of notes payable and accrued interest	$ 26	53,697		53,723
Conversion of notes payable and accrued interest (in Shares)	268,615
Net loss			(458,570)	(458,570)
Balance at Mar. 31, 2019	$ 15,461	19,061,861	(22,179,792)	(3,102,470)
Balance (in Shares) at Mar. 31, 2019	154,621,112
Balance at Dec. 31, 2018	$ 15,429	18,981,570	(21,721,222)	(2,724,223)
Balance (in Shares) at Dec. 31, 2018	154,292,497
Net loss				458,570
Balance at Dec. 31, 2019	$ 15,631	20,159,540	(23,888,766)	$ (3,713,595)
Balance (in Shares) at Dec. 31, 2019	156,316,112			156,316,112
Common stock issued to directors and employees	$ 130	303,333		$ 303,463
Common stock issued to directors and employees (in Shares)	1,298,224
Common stock issues for settlement	$ 16	37,984		38,000
Common stock issues for settlement (in Shares)	160,000
Stock options issued to directors and employees as compensation		381,475		381,475
Net loss			(1,444,392)	(1,444,392)
Balance at Mar. 31, 2020	$ 15,777	$ 20,882,332	$ (25,333,158)	$ (4,435,049)
Balance (in Shares) at Mar. 31, 2020	157,774,336			157,774,336

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (1,444,392)	$ (458,570)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Non-cash stock compensation issued for services	38,000	26,600
Non-cash stock compensation issued to employees	303,463	0
Fair value of stock options issued to employees	381,475	0
Amortization of discount on notes payable	39,918	93,237
Amortization of leasehold right of use asset	5,529	0
Depreciation and amortization	2,980	1,971
Changes in assets and liabilities:
Accounts receivable	3,859	151,182
Inventories	(60,896)	(8,172)
Prepaid expenses and other current assets	22,675	22,758
Deferred revenue	(178,572)	4,821,428
Accounts payable and accrued expenses	(76,791)	20,249
Leasehold liability	(5,163)	0
Accrued interest - related party	10,321	0
Accrued compensation	94,144	(1,582,595)
Net cash provided by (used in) operating activities	(863,450)	3,088,088
Cash from investing activities:
Payments to acquire property, plant and equipment	(20,528)	(48,400)
Payments to acquire property, plant and equipment	(4,607)	0
Net cash (used) in investing activities	(25,135)	(48,400)
Cash from financing activities:
Principal payments on note payable - related parties	0	(62,743)
Cash paid for notes payable	0	(131,722)
Net cash (used in) provided by financing activities	0	(194,465)
Increase (decrease) in cash and cash equivalents	(888,585)	2,845,223
Cash and cash equivalents at beginning of period	1,238,585	212,243
Cash and cash equivalents at end of period	350,000	3,057,466
Cash paid during the period for:
Interest	0	9,879
Taxes	0	912
Common stock issued for conversion of notes payable and accrued interest	$ 0	$ 53,723

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 – Basis of Presentation The accompanying unaudited condensed consolidated balance sheets as of March 31, 2020 and December 31, 2019, the condensed consolidated statements of operations, stockholders’ deficiency and cash flows for the three months ended March 31, 2020 and 2019 of INVO Bioscience, Inc. (the “Company”), and the related information contained in these notes have been prepared by management and are unaudited. In the opinion of management, all adjustments (which include normal recurring and nonrecurring items) necessary to present fairly the Company’s financial position, results of operations and cash flows in conformity with generally accepted accounting principles for the periods presented have been made. Interim operating results are not necessarily indicative of operating results for a full year. The preparation of our unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Certain information and note disclosures normally included in the Company’s annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2018 Annual Report on Form 10-K previously filed by the Company with the Securities and Exchange Commission (SEC). The Company considers events or transactions that have occurred after the unaudited condensed consolidated balance sheet date of March 31, 2020, but prior to the filing of the unaudited condensed consolidated financial statements with the SEC on this Quarterly Report on Form 10-Q, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure, as applicable. Subsequent events have been evaluated through the date of the filing of this Quarterly Report on Form 10-Q with the SEC.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2020
Accounting Standards Update and Change in Accounting Principle [Abstract]
Accounting Standards Update and Change in Accounting Principle [Text Block]	Note 2 – Recent Accounting Pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASUs”) to the FASB’s Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. ASUs not listed below were assessed and determined not to be applicable or are expected to have minimal impact on the Company’s consolidated financial position and results of operations. Recently Adopted Accounting Pronouncements In February 2016, FASB issued ASU 2016-02, Leases (“ASU 2016-02”). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The adoption of the new standard did not have an impact on the Company’s consolidated financial statements.

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	Note 3 – Going Concern On January 14, 2019, INVO Bioscience entered into a distribution agreement (the “Distribution Agreement”) with Ferring International Center S.A. (“Ferring”) which granted Ferring an exclusive licensing rights to sublicense the Company’s INVOcell together with the retention device for the U.S. market. Under the terms of the Distribution Agreement, Ferring was obligated to make an initial payment to the Company of $5,000,000 upon satisfaction of certain closing conditions. The Company received the initial $5 million cash payment upon the execution of the Ferring distribution agreement in January 2019. For the three months ended March 31, 2020 and 2019, we had net losses of $1,444,392 and $458,570, respectively. We had a working capital deficiency of $1,234,432 in the three months ended March 31, 2020 verses working capital as of December 31, 2019 of $42,330. As of March 31, 2020, our stockholder’s deficiency was $4,435,049 compared to $3,713,595 as of December 31, 2019 and cash used in operations was $863,450 for the three months ended March 31, 2020 compared to cash provided by operations of $3,088,088 for the three months ended March 31, 2019. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. Based on our projected cash needs, we will be dependent on generating sufficient sales, entering into new distribution agreements, or raising additional debt or equity capital to support our plans over the next 12 months.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Note 4 – Inventory As of March 31, 2020, and December 31, 2019, the Company recorded the following inventory balances: March 31, 2020 December 31, 2019 Raw Materials $ 66,763 $ 44,333 Work in Process - 55,502 Finished Goods 95,520 1,552 Total Inventory, net $ 162,283 $ 101,387

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 5 – Property and Equipment The estimated useful lives and accumulated depreciation for furniture, equipment and software are as follows as of March 31, 2020 and December 31, 2019: Estimated Useful Life Manufacturing equipment 6 to 10 years Medical equipment 10 years Office equipment 3 to 7 years March 31, 2020 December 31, 2019 Manufacturing Equipment $ 132,513 $ 132,513 Medical equipment 20,528 - Office equipment 2,689 2,689 Accumulated Depreciation (44,675 ) (42,147 ) Total $ 111,055 $ 93,055 During the three months ended March 31, 2020 and 2019 the Company recorded depreciation expense of $2,528 and $1,137, respectively.

Patents

Patents	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	Note 6 – Patents As of March 31, 2020, and December 31, 2019, the Company recorded the following patent balances: March 31, 2020 December 31, 2019 Total Patents $ 77,722 $ 77,722 Accumulated Amortization (70,940 ) (70,488 ) Patent costs, net $ 6,782 $ 7,234 During the three ended March 31, 2020 and 2019, the Company recorded $452 and $834 in amortization expense, respectively. Estimated amortization expense as of March 31, 2020 is as follows: Years ended December 31, 2020 – remaining nine months $ 1,357 2021 1,809 2022 1,809 2023 1,807 2024 and thereafter - Total $ 6,782 As of March 31, 2020, and December 31, 2019, the Company recorded the following trademarks balances: March 31, 2020 December 31, 2019 Total Trademarks $ 54,474 $ 49,867 Accumulated Amortization - - Trademarks, net $ 54,474 $ 49,867 The trademarks have an indefinite life, so no amortization expense is calculated. Trademarks are periodically reviewed for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. The Trademark assets were created in 2019 and no material adverse changes have occurred since their creation.

Leases

Leases	3 Months Ended
	Mar. 31, 2020
Disclosure Text Block [Abstract]
Lessor, Operating Leases [Text Block]	Note 7 – Leases The Company has an operating lease for our facility, which have an initial term of 5 years with an option to renew for 3 additional years. They also do not have an early termination clause included. Our operating lease agreements do not contain any material restrictive covenants. Per FASB’s ASU 2016-02, Leases (Topic 842), effective January 1, 2019, the company is required to report a right-of-use asset and corresponding liability to report the present value of the total least payments, with appropriate interest calculation. Per the terms of ASU 201-02, the company can use its implicit interest rate, if known, or applicable federal rate otherwise. Since the company’s implicit interest rate was not readily determinable, we utilized the applicable federal rate, which was 3.0% as of April 2019. As of March 31, 2020, the Company's lease components included in the consolidated balance sheet were as follows: Lease component Classification March 31, 2020 Assets ROU assets - operating lease Other assets $ 96,354 Total ROU assets $ 96,354 Liabilities Current operating lease liability Current liabilities $ 21,704 Long-term operating lease liability Other liabilities 75,992 Total lease liabilities $ 97,696 Rent expense is recognized on a straight-line basis over the life of the lease. Rent expense consists of the following: Three months ended March 31, 2020 Operating lease costs $ 6,288 Total rent expense $ 6,288 Future minimum lease payments under non-cancellable leases were as follows: March 31, 2020 2020 - remaining nine months $ 18,239 2021 24,886 2022 25,633 2023 26,402 2024 8,886 2025 and beyond - Total future minimum lease payments $ 104,046 Less: Interest 6,350 Total operating lease liabilities $ 97,696 Current operating lease liability $ 21,704 Long-term operating lease liability 75,992 Total operating lease liabilities $ 97,696

Notes Payable

Notes Payable	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Long-term Debt [Text Block]	Note 8 – Notes Payable Notes Payable In August 2016, INVO Bioscience converted a long-time vendor’s outstanding accounts payable balance of $131,722 into a Promissory Note with a three year term that accrues interest at 5% per annum. The note provides for interest only payments on the first and second anniversaries of the note. The note is payable in full along with any outstanding accrued interest on August 9, 2019. The Company has the right to prepay the note at any time without a premium or penalty which it did in January 2019. The interest on this note for the three months ended March 31, 2019 was $489. The Note and all accrued interest were paid in full and as of March 31, 2020, the balance is $0. 2018 Convertible Notes Payable In April and May 2018, the Company issued convertible notes (the “2018 Convertible Notes”) payable to investors’ in the aggregate principal amount of $895,000. The 2018 Convertible Notes accrue interest at the rate of 9% per annum which is paid in stock. 2018 Convertible Notes with an aggregate principal amount of $550,000 are due on January 30, 2021, and 2018 Convertible Notes with an aggregate principal amount of $345,000 are due on March 31, 2021. The notes are convertible into shares of common stock at a price of $0.20 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes can elect to convert the notes in shares of our common stock at a price equal to 75% of the price paid per share in such subsequent equity financing. During the fourth quarter of 2018, three note holders converted their notes with a value of $200,000 into 1,055,415 shares of common stock. During the three months ended March 31, 2019, a note holder converted principal and accrued interest of $50,000 and $3,723, respectively, into 268,615 shares of common stock. The Company calculated a beneficial conversion feature of the 2018 Convertible Notes based on ASU 17-11 in the form of a discount of $895,000; $36,487 and $93,237 of this amount was amortized to interest expense during the three months ended March 31, 2020 and 2019, respectively, based on the three year term of the notes. $37,377 was also amortized for a note that was converted during the first quarter of 2019. In addition, $9,424 and $14,870 of interest was expensed in the three months ended March 31, 2020 and 2019, respectively. The balance of these notes as of March 31, 2020 was $371,695 include the principal balance of $420,000, accrued interest of $89,518 net of the conversion discount of $137,823. The balance of these notes as of December 31, 2019 was $325,784 include the principal balance of $420,000, accrued interest of $80,094 net of the conversion discount of $191,461.

Notes Payable and Other Related

Notes Payable and Other Related Party Transactions	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 9 – Notes Payable and Other Related Party Transactions In April 2011, the Company issued a new short-term convertible note (“Q211 Note”) payable to James Bowdring in the amount of $50,000. The Note carries a 10% interest rate. The Company paid $25,000 of the Note in 2011 in cash. The Q211 Note is convertible into Common Stock of the Company at a conversion price of $0.03 per share, subject to adjustments. During the three months ended March 2020 and March 31, 2019, the Company accrued interest in the amount of $0 and $616 on the Q211 Note, respectively. In November 2011, the Company issued a new convertible note (“Q411 Note”) payable to James Bowdring in the amount of $10,000. The Q411 Note carries a 10% interest rate. The Q411 Note was converted into Common Stock of the Company at a conversion price of $0.01 per share, subject to adjustments. In addition, $0 and $247 of interest was accrued in the three months ended March 31, 2020 and 2019, respectively. On August 7, 2019, the Company sent James Bowdring, a related party, a check in the amount of $65,197 as full payment under those certain promissory notes dated April 8, 2011 and November 9, 2011. On August 8, 2019, Mr. Bowdring’s legal counsel returned this check with a letter stating that the check did not properly account for the compound interest identified in such notes. In addition, the letter stated Mr. Bowdring’s desire to convert these promissory notes into shares of the Company’s common stock in lieu of any cash payment. The Company does not believe that Mr. Bowdring has the right to convert such notes upon receiving payment of such notes and intends to vigorously contend any conversion of these notes. The 10% Senior Secured Convertible Promissory Notes were issued on April 8, 2011 and November 9, 2011, with maturity dates thirty days subsequent to the dates of issuance. Interest was calculated at 10% per annum, compounded based on a 360-day year. Investors had the option to convert any unpaid principal and accrued interest into shares of Company’s common stock original conversion prices of $.03 and $.01, respectively, subject to adjustments upon the Company’s issuances of stock at prices less than the original conversion prices during the 24-months after issuance of each note (i.e. currently $0.0065). In May 2018, James Bowdring and his children participated in the “2018 Convertible Notes” offerings in the aggregate principal amount of $40,000. The 2018 Convertible Notes accrue interest at the rate of 9% per annum which is paid in stock. These Notes are due on March 31, 2021. The notes are convertible into shares of common stock at a price of $0.20 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes can elect to convert the notes in shares of our common stock at a price equal to 75% of the price paid per share in such subsequent equity financing. In addition, $3,431 and $3,393 of interest was accrued in the three months ended March 31, 2020 and 2019, respectively. In May 2018, the Company sold 150,000 shares of common stock at a price of $0.20 per share for proceeds of $30,000 to Charles Mulrey and family, the brother-in-law of Robert J. Bowdring, Director & Acting Chief Financial Officer as part of the recent financing. During the second quarter of 2018, INVO Bioscience settled a commitment it had with one of its Directors, Dr. Kevin Doody for the services he and his team performed prior to and following INVOcell’s FDA clearance related to clinical guidance and support. The Company issued him 3 million common shares of stock with a fair value of $1,530,000. The Company previously rented its corporate office from Forty Four Realty Trust which is owned by James Bowdring, the brother of former Director and interim CFO, Robert Bowdring from November 2012 through May 2019 when the company relocated to a new facility. It was a month to month rental arrangement for less than the going fair market real estate rental rate. The rent expense paid for the three months ended March 31, 2020 and 2019 was $0 and $1,800 respectively. In addition, the Company previously purchased stationary supplies and marketing items at discounted rates from Superior Printing & Promotions which is also owned by James Bowdring and was in the same building as our prior corporate office. INVO Bioscience spent $0 and $778 with Superior during the three months ended March 31, 2020 and 2019, respectively. Principal balances of the Related Party loans were as follows: March 31, 2020 December 31, 2019 James Bowdring Family – 2018 Convertible Notes 46,872 45,975 Less discount (13,720 ) (17,151 ) Total, net of discount $ 33,152 $ 28,824 Interest expense on the Related Party loans was $897 and $1,751 for the three months ended March 31, 2020 and 2019, respectively. Accounts payable and accrued liabilities balances include expenses reports for Ms. Karloff and Mr. Bowdring for expenses they paid for personally related to travel or normal business expenses. As of March 31, 2020, they were $0 and as of December 31, 2019, they were $13,018.

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2020
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 10 – Stockholders’ Equity Three Months Ended March 31, 2020 In January 2020, the Company issued 1,000,000 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $221,400 to an officer. In February 2020, the Company issued 100,000 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $24,750 to an employee. In February 2020, the Company issued 99,112 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $25,000 to a board member. In February 2020, the Company issued 99,112 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $25,000 to a board member. In February 2020, the Company issued 60,000 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $15,000 for consulting services. In February 2020, pursuant to Section 4(a)(2) of the Securities Act of 1933 as amended (the “Securities Act”), the Company issued 50,000 shares of common stock with a fair value of $11,500 in consideration of consulting services rendered. We did not receive any proceeds from the issuance. In March 2020, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 50,000 shares of common stock with a fair value of $11,500 in consideration of consulting services rendered. We did not receive any proceeds from the issuance. Three Months Ended March 31, 2019 In January 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 60,000 shares of common stock with a fair value of $26,600 to service providers. In February 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 268,615 shares of common stock for conversion of notes payable and accrued interest in the amount of $53,723.

Stock Options and Warrants

Stock Options and Warrants	3 Months Ended
	Mar. 31, 2020
Disclosure Text Block Supplement [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	Note 11 – Stock Options and Warrants Equity Incentive Plans In October 2019, we adopted our 2019 Stock Incentive Plan (the "2019 Plan"). Under the 2019 Plan, our Board of Directors is authorized to grant both incentive and non-statutory stock options to purchase common stock and restricted stock awards to our employees, directors, and consultants. The 2019 Plan provides for the issuance of 16,000,000 shares. Options generally have a life of 3 to 10 years and exercise price equal to or greater than the fair market value of the Common Stock as determined by the Board of Directors. Vesting for employees typically occurs over a three-year period or based on performance objective. The following table sets forth the activity of the options to purchase common stock under the 2019 Plan. The prices represent the closing price of our Common Stock on the OTCQB Market on the respective dates. Options Outstanding Options Exercisable Number of Shares Price per Share Range Weighted Average Exercise Price Aggregate Intrinsic Value (1) Number of Shares Weighted Average Exercise Price Aggregate Intrinsic Value (1) Balance at December 31, 2019 8,320,587 $ 0.26-0.29 $ 0.26 $ - 360,176 $ 0.26 $ - Forfeited - $ - $ - - - - - Vested 1,998,544 0.23 Exercised - $ - $ - - - - - Granted 5,275,560 $ 0.21-0.26 $ 0.22 - - - - Balance at March 31, 2020 13,596,147 $ 0.21-0.29 $ 0.25 $ - 2,358,720 $ 0.23 $ - (1) The intrinsic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the option of in-the-money options only. The fair value of each option granted is estimated as of the grant date using the Black-Scholes option pricing model with the following assumptions: Three Months ended March 31, 2020 2019 Risk-free interest rate range 0.48 to 1.65 % -% Expected life of option-years 5.20 to 5.77 - Expected stock price volatility 110.8 to 128.0 % - % Expected dividend yield - % - % The risk-free interest rate is based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the stock options. Expected volatility is based upon the average historical volatility of our common stock over the period commensurate with the expected term of the related instrument. The expected life and estimated post-employment termination behavior is based upon historical experience of homogeneous groups, executives and non-executes, within our company. We do not currently pay dividends on our common stock nor do we expect to in the foreseeable future. Options Outstanding Options Exercisable Range of Exercise Prices Options Outstanding Weighted Average Remaining Life in Years Weighted Average Exercise Price Options Exercisable Weighted Average Exercise Price of Options Exercisable Year ended December 31, 2019 $ 0.26-0.29 8,320,587 2.6 $ 0.26 360,176 $ 0.26 Three Months ended March 31, 2020 $ 0.21-0.29 13,596,147 3.6 $ 0.25 2,358,720 $ 0.23 Total Intrinsic Value of Options Exercised Total Fair Value of Options Vested Year ended December 21, 2019 - 69,787 Three months ended March 31, 2020 $ - $ 378,537 For the three months ended March 31, 2020, the weighted average grant date fair value of options granted was $0.20 per share. We estimate the fair value of options at the grant date using the Black-Scholes model. For all stock options granted through December 31, 2019, the weighted average remaining service period is 3.6 years. We recognized $381,475 in stock-based compensation expense, which is recorded in selling, general and administrative expenses on the consolidated statement of operations for the three months ended March 31, 2020 and 2019. Unamortized stock option expense at March 31, 2020 that will be amortized over the weighted-average remaining service period totaled $1,794,251. Restricted Stock and Restricted Stock Units In the three months ended March 31, 2020, we issued 1,398,224 of restricted stock, to certain employees and directors. Shares issued to employees and directors vest over a time frame from immediate to 1 year. In the three months ended March 31, 2020, 1,157,889 shares of restricted stock vested. The following table summarizes our aggregate restricted stock awards and restricted stock unit activity during the three months ended March 31, 2020: Number of Unvested Shares Weighted Average Grant Date Fair Value Aggregate Value of Unvested Shares Balance at December 31, 2019 333,334 $ 0.30 $ 100,000 Granted 1,398,224 $ 0.23 $ 320,140 Vested (1,157,889 ) $ 0.23 $ (265,963 ) Forfeitures (- ) $ - $ (- ) Balance at March 31, 2020 573,669 $ 0.27 $ 154,178 We recognized $265,963 in stock-based compensation expense, which is recorded in selling, general and administrative expenses on the consolidated statement of operations for the three months ended March 31, 2020, and we will recognize $154,178 over the remaining requisite service period. Warrants As of March 31, 2020, and 2019, the Company does not have any outstanding or committed and unissued warrants.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 12 – Income Taxes The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a carryforward exists, the Company makes a determination as to whether the carryforward will be utilized in the future. Currently, a valuation allowance is established for all DTA’s and carryforwards as their recoverability is deemed to be uncertain. If our expectations for future operating results at the federal or at the state jurisdiction level vary from actual results due to changes in healthcare regulations, general economic conditions, or other factors, we may need to adjust the valuation allowance, for all or a portion of our deferred tax assets. Our income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings. Income tax expense was $0 and $0 for the three months ended March 31, 2020 and 2019. The annual forecasted effective income tax rate for 2020 is 0% with a year-to-date effective income tax rate for the three months ended March 31, 2020 of 0%.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 13 – Commitments and Contingencies A) Litigation INVO Bioscience, Inc. v. James Bowdring On August 7, 2019, the Company sent James Bowdring, the brother of our then Chief Financial Officer, a check in the amount of $65,197 as full and final payment under those certain promissory notes dated April 8, 2011 and November 9, 2011. On August 8, 2019, Mr. Bowdring’s legal counsel returned the check. A basis for returning the check was a claim that the interest due under the Notes called for compounded interest and not per annum interest. In addition, the letter rejecting the tender of the payment in full check alleged Mr. Bowdring was considering a future intention to convert his Promissory Notes into shares of the Company’s common stock. Mr. Bowdring, through his counsel, indicated that such future intention to convert the Notes to common stock were contingent upon Mr. Bowdring addressing certain personal issues which were not disclosed by his counsel in the correspondence returning the checks. The Company does not believe that Mr. Bowdring has the right to seek conversion of the Notes once payment for the Notes has been tendered. In order to resolve the issue of the Company’s tender of payment in full versus Mr. Bowdring’s assertion that he can reject tender and seek conversion, the Company has filed an action in the Suffolk Superior Court in Boston on September 3, 2019 seeking Declaratory Judgment and Judgment for Breach of Contract. On September 30, 2019, Mr. Bowdring filed an answer and counterclaim under which he alleged breach of contract, fraud, promissory estoppel, unfair and deceptive practices and constructive trust. Mr. Bowdring is seeking receipt of all shares due under the adjusted conversion price. The 10% Senior Secured Convertible Promissory Notes were issued on April 8, 2011 and November 9, 2011, with maturity dates thirty days subsequent to the dates of issuance. Interest was calculated at 10% per annum, compounded based on a 360-day year. Investors had the option to convert any unpaid principal and accrued interest into shares of Company’s common stock original conversion prices of $.03 and $.01, respectively, subject to adjustments upon the Company’s issuances of stock at prices less than the original conversion prices during the 24-months after issuance of each note (i.e. currently $0.0065). The Company does not currently expect the above matter to have a material adverse effect upon either our results of operations, financial position, or cash flows. B) Employee Agreements On October 10, 2019, we entered into an agreement with our newly appointed CEO, Steve Shum. We agreed to pay Mr. Shum an annual salary of $260,000. In addition, Mr. Shum is eligible to earn bonus compensation of up to $75,000 bonus upon a successful up-listing to the NASDAQ exchange. All other bonus amounts will be determined by the Board of Directors, in their sole discretion. In addition to his base salary and performance bonus, we granted Mr. Shum: (i) 400,000 shares of our common stock and (ii) a three-year option to purchase 6,483,171 shares of our common stock at an exercise price of $0.255 per share. These options will vest monthly over a 3-year period. On January 15, 2020, INVO Bioscience, Inc. (the “ Company Employment Agreement In connection with the Employment Agreement, on January 17, 2020, the Company granted Mr. Campbell 1,000,000 shares of Company common stock, and an option to purchase 4,000,000 shares of Company common stock (the “ Option The Company has entered into a consulting agreement with Shine Management, Inc. through which it is receiving outsourced accounting and the support of its acting CFO, Debra Hoopes. Debra is the CFO and Chief Administrative Officer of Shine Management, Inc. and Management Services Company in Charlottesville, VA.

Contracts with Customers

Contracts with Customers	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	Note 14 – Contracts with Customers We have adopted ASC 606, Revenue from Contracts with Customers . Revenue Recognition Revenues for products, including: INVOcell ® TM In January 2019 we announced a U.S. license and distribution agreement with Ferring International Center S.A. (“Ferring”) and as a result took a significant step to strengthen the Company that we believe will allow us to implement our overall business plan. We believe that this strategic partnership with a strong reproductive organization such as Ferring Pharmaceuticals will provide us with the necessary sales and marketing resources within the United States to expand the market and help reach couples not receiving reproductive treatments today. The agreement calls for the issuance of an initial upfront payment of $5 million which we received upon the signing of the agreement and then subsequent licensing fee payment of $3,000,000 that will provides us a source of non-dilutive financing to execute our plan. Under the terms of the agreement we can pursue developing international markets and as well as partnering and opening INVO-only reproductive centers within the U.S. market. We believe this major milestone and agreement was a critical milestone that allows the Company to implement its mission of expanding access to care within the fertility marketplace. Under the terms of the Distribution Agreement, Ferring completed its obligation to make an initial payment to the Company of $5,000,000 upon completion of the required closing conditions, including executed agreements from all current manufacturers of the Licensed Product that upon a material supply default by the Company, Ferring can assume a direct purchase relationship with such manufacturers. Ferring is obligated to make a second payment to the Company of $3,000,000 provided that the Company is successful in obtaining a five (5) day label enhancement from the FDA for the current incubation period for the Licensed Product at least three (3) years prior to the expiration of the term of the license for the Licensed Product and provided further that Ferring has not previously exercised its right to terminate the Distribution Agreement for convenience. In addition, the Company entered into a separate exclusive Distribution Agreement. The Distribution Agreement has an initial term expiring on December 31, 2025, which may be terminated by the Company if Ferring fails to generate specified annual minimum revenues to the Company from the sale of the Licensed Product. The Ferring license was deemed to be a functional licenses that provide customers with a “right to access” to our intellectual property during the subscription period and, accordingly, revenue is recognized over a period of time, which is generally the subscription period. During the quarter ended March 31, 2020, the Company recognized $178,571 related to the Ferring license agreement. As of March 31, 2020, and December 31, 2019, the Company had deferred revenues of $4,107,143 and $4,477,261, respectively. On September 20, 2019, we entered into an exclusive distribution agreement with Quality Medicines, Cosmetics & Medical Equipment Import for the territories of Sudan, Uganda and Ethiopia. This distribution agreement has a term of one year and may be extended by mutual agreement and is based on wholesale prices. Quality Medicines is required to register our product in each of these countries. On September 11, 2019, we entered into an exclusive distribution agreement with G-Systems Limited registered in Nigeria. In the territories of Nigeria. This distribution agreement has a term of one year and may be extended by mutual agreement and is based on wholesale prices. G-Systems is required to register our produce in Nigeria. On November 12, 2019, we announced we had entered into exclusive distribution agreements with Biovate a Jordanian company for the territory of Jordan and Orcan Medical for the territory of Turkey. This agreement has a term of one year with extensions by mutual agreement. Safadi Drugstore is required to register our product in Jordan. On January 16, 2020, we announced a Joint Venture agreement for the India Market. Under terms of the agreement, INVO Bioscience and our Partner, Medesole Healthcare and Trading Pvt Ltd, will each own 50% of the joint venture. We provide the device, training and general technology support to the joint venture, while Medesole will be responsible for the operations of the INVOcell clinics in India. Both partners will equally invest in start-up and capital expenditures and share in the revenue and profits of the joint venture. The business model allows INVO to benefit not only from the sale of the device, but from the delivery of the entire solution. We believe this JV structure is an attractive new model for us, and one in which we may replicate in other select parts of the world. As of March 31, 2020 the final JV setup had not yet been completed. We currently anticipate this to occur during the second quarter of 2020. Sources of Revenue We have identified the following revenues disaggregated by revenue source: Domestic Physicians – direct sales of products concluded in January 2019 Domestic Distributor - sales to Ferring who then sells to physicians Domestic Licensing fee International Distributors – direct sales of products. March 31, 2020 (unaudited) For the three months ended March 31, 2020 and 2019 the source of revenue was derived from: March 31, 2020 March 31, 2019 Domestic product revenue $ 80,000 $ 10,860 Domestic Licensing Fee 178,571 178,572 Total revenue $ 258,571 $ 189,432 Contract Balances We incur agreement obligations on general customer purchase orders and e-mails that have been accepted but unfulfilled. Due to the short duration of time between order acceptance and delivery of the related product, we have determined that the balance related to these obligations is generally immaterial at any point in time. We monitor the value of orders accepted but unfulfilled at the close of each reporting period to determine if disclosure is appropriate. Warranty Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations. Significant Judgments in the Application of the Guidance in ASC 606 There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon delivery of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Therefore, the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial. We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary. Commissions and Contract Costs We do not use or offer sales commissions of any type at this time. We generally do not incur incremental charges associated with securing agreements with customers which would require capitalization and recovery over the life of the agreement. Practical Expedients Our payment terms for sales direct to customers and distributors are substantially less than the one year collection period that falls within the practical expedient in determination of whether a significant financing component exists. Shipping and Handling Charges Fees charged to customers for shipping and handling of products are included as an offset to the costs for shipping and handling of products included as a component of cost of products. Taxes Collected from Customers As our products are used in another service and are exempt, to this point we have not collected taxes. If we were to collect taxes they would be on the value of transaction revenue and would be excluded from product revenues and cost of sales and would be accrued in current liabilities until remitted to governmental authorities. Effective Date and Transition Disclosures Adoption of the new standards related to revenue recognition did not have a material impact on our consolidated financial statements and is not expected to have a material impact in future periods.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 15 – Subsequent Events Effective May 15, 2020, we entered into definitive securities purchase agreements (“Purchase Agreements”) with accredited investors for their purchase of (i) secured convertible notes issued by us in the aggregate original principal amount of $2,105,000 (the “Notes”), and (ii) Unit Purchase Options (“Purchase Options”) to purchase 5,851,900 units (each, a “Unit”), at an exercise price of $0.25 per Unit (subject to adjustments). with each Unit exercisable for (A) one share of our common stock and (B) a 5-year warrant (the “Warrants”) to purchase one share of our common stock at an exercise price of $0.30 (subject to adjustments) (the “Private Placement”). Each purchaser of a Note will be issued a 5-year Purchase Option to purchase 2.78 Units for each dollar of Notes purchased Upon closing of the sale of the Notes and Purchase Options (the “Closing”), we are expected to receive proceeds of $2.105 million (of which $1,961,360 was received in cash and $143,640 resulted from cancellation of indebtedness). Tribal Capital Markets, LLC acted as placement agent (the “Placement Agent”) in the Private Placement. The Company received approximately $1.75 million in net proceeds at Closing, after deducting placement agent fees payable to the Placement Agent and investor counsel in connection with the transaction. Pursuant to that certain Form of Secured Convertible Note entered into in connection with the Purchase Agreement (the “Form of Note”), interest on such Notes accrues at a rates of ten percent (10%) per annum and is payable either in cash or in shares of our common stock at the conversion price in the Note on each of the six and twelve month anniversary of the issuance date and on the maturity date of November 15, 2021 (the “Maturity Date”). In May 2020, the Company issued 230,000 shares of common stock under its 2019 Stock Incentive Plan with a fair value of $48,730 to certain employees. The Company has evaluated subsequent events through the date the financial statements were released and there were no others.

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	As of March 31, 2020, and December 31, 2019, the Company recorded the following inventory balances: March 31, 2020 December 31, 2019 Raw Materials $ 66,763 $ 44,333 Work in Process - 55,502 Finished Goods 95,520 1,552 Total Inventory, net $ 162,283 $ 101,387

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2020
Property and Equipment (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]	The estimated useful lives and accumulated depreciation for furniture, equipment and software are as follows as of March 31, 2020 and December 31, 2019: March 31, 2020 December 31, 2019 Manufacturing Equipment $ 132,513 $ 132,513 Medical equipment 20,528 - Office equipment 2,689 2,689 Accumulated Depreciation (44,675 ) (42,147 ) Total $ 111,055 $ 93,055
Estimated Useful Life [Member]
Property and Equipment (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]	The estimated useful lives and accumulated depreciation for furniture, equipment and software are as follows as of March 31, 2020 and December 31, 2019: Estimated Useful Life Manufacturing equipment 6 to 10 years Medical equipment 10 years Office equipment 3 to 7 years

Patents (Tables)

Patents (Tables)	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	As of March 31, 2020, and December 31, 2019, the Company recorded the following patent balances: March 31, 2020 December 31, 2019 Total Patents $ 77,722 $ 77,722 Accumulated Amortization (70,940 ) (70,488 ) Patent costs, net $ 6,782 $ 7,234
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Estimated amortization expense as of March 31, 2020 is as follows: Years ended December 31, 2020 – remaining nine months $ 1,357 2021 1,809 2022 1,809 2023 1,807 2024 and thereafter - Total $ 6,782
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	As of March 31, 2020, and December 31, 2019, the Company recorded the following trademarks balances: March 31, 2020 December 31, 2019 Total Trademarks $ 54,474 $ 49,867 Accumulated Amortization - - Trademarks, net $ 54,474 $ 49,867

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Disclosure Text Block [Abstract]
Lessee, Operating Lease, Disclosure [Table Text Block]	As of March 31, 2020, the Company's lease components included in the consolidated balance sheet were as follows: Lease component Classification March 31, 2020 Assets ROU assets - operating lease Other assets $ 96,354 Total ROU assets $ 96,354 Liabilities Current operating lease liability Current liabilities $ 21,704 Long-term operating lease liability Other liabilities 75,992 Total lease liabilities $ 97,696
Lease, Cost [Table Text Block]	Rent expense is recognized on a straight-line basis over the life of the lease. Rent expense consists of the following: Three months ended March 31, 2020 Operating lease costs $ 6,288 Total rent expense $ 6,288
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Future minimum lease payments under non-cancellable leases were as follows: March 31, 2020 2020 - remaining nine months $ 18,239 2021 24,886 2022 25,633 2023 26,402 2024 8,886 2025 and beyond - Total future minimum lease payments $ 104,046 Less: Interest 6,350 Total operating lease liabilities $ 97,696 Current operating lease liability $ 21,704 Long-term operating lease liability 75,992 Total operating lease liabilities $ 97,696

Notes Payable and Other Relat_2

Notes Payable and Other Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	Principal balances of the Related Party loans were as follows: March 31, 2020 December 31, 2019 James Bowdring Family – 2018 Convertible Notes 46,872 45,975 Less discount (13,720 ) (17,151 ) Total, net of discount $ 33,152 $ 28,824

Stock Options and Warrants (Tab

Stock Options and Warrants (Tables)	3 Months Ended
	Mar. 31, 2020
Disclosure Text Block Supplement [Abstract]
Schedule of Stock Options Roll Forward [Table Text Block]	The following table sets forth the activity of the options to purchase common stock under the 2019 Plan. The prices represent the closing price of our Common Stock on the OTCQB Market on the respective dates. Options Outstanding Options Exercisable Number of Shares Price per Share Range Weighted Average Exercise Price Aggregate Intrinsic Value (1) Number of Shares Weighted Average Exercise Price Aggregate Intrinsic Value (1) Balance at December 31, 2019 8,320,587 $ 0.26-0.29 $ 0.26 $ - 360,176 $ 0.26 $ - Forfeited - $ - $ - - - - - Vested 1,998,544 0.23 Exercised - $ - $ - - - - - Granted 5,275,560 $ 0.21-0.26 $ 0.22 - - - - Balance at March 31, 2020 13,596,147 $ 0.21-0.29 $ 0.25 $ - 2,358,720 $ 0.23 $ - (1) The intrinsic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the option of in-the-money options only.
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of each option granted is estimated as of the grant date using the Black-Scholes option pricing model with the following assumptions: Three Months ended March 31, 2020 2019 Risk-free interest rate range 0.48 to 1.65 % -% Expected life of option-years 5.20 to 5.77 - Expected stock price volatility 110.8 to 128.0 % - % Expected dividend yield - % - %
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	The risk-free interest rate is based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the stock options. Expected volatility is based upon the average historical volatility of our common stock over the period commensurate with the expected term of the related instrument. The expected life and estimated post-employment termination behavior is based upon historical experience of homogeneous groups, executives and non-executes, within our company. We do not currently pay dividends on our common stock nor do we expect to in the foreseeable future. Options Outstanding Options Exercisable Range of Exercise Prices Options Outstanding Weighted Average Remaining Life in Years Weighted Average Exercise Price Options Exercisable Weighted Average Exercise Price of Options Exercisable Year ended December 31, 2019 $ 0.26-0.29 8,320,587 2.6 $ 0.26 360,176 $ 0.26 Three Months ended March 31, 2020 $ 0.21-0.29 13,596,147 3.6 $ 0.25 2,358,720 $ 0.23 Total Intrinsic Value of Options Exercised Total Fair Value of Options Vested Year ended December 21, 2019 - 69,787 Three months ended March 31, 2020 $ - $ 378,537
Nonvested Restricted Stock Shares Activity [Table Text Block]	The following table summarizes our aggregate restricted stock awards and restricted stock unit activity during the three months ended March 31, 2020: Number of Unvested Shares Weighted Average Grant Date Fair Value Aggregate Value of Unvested Shares Balance at December 31, 2019 333,334 $ 0.30 $ 100,000 Granted 1,398,224 $ 0.23 $ 320,140 Vested (1,157,889 ) $ 0.23 $ (265,963 ) Forfeitures (- ) $ - $ (- ) Balance at March 31, 2020 573,669 $ 0.27 $ 154,178

Contracts with Customers (Table

Contracts with Customers (Tables)	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue [Table Text Block]	For the three months ended March 31, 2020 and 2019 the source of revenue was derived from: March 31, 2020 March 31, 2019 Domestic product revenue $ 80,000 $ 10,860 Domestic Licensing Fee 178,571 178,572 Total revenue $ 258,571 $ 189,432

Going Concern (Details)

Going Concern (Details) - USD ($)	Jan. 14, 2019	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Proceeds from License Fees Received	$ 5,000,000			$ 5,000,000
Net Income (Loss) Attributable to Parent		$ (1,444,392)	$ (458,570)	458,570
Working Capital (Deficit)		(1,234,432)		42,330
Stockholders' Equity Attributable to Parent		(4,435,049)	(3,102,470)	$ (3,713,595)	$ (2,724,223)
Net Cash Provided by (Used in) Operating Activities		$ (863,450)	$ 3,088,088

Inventory (Details) - Schedule

Inventory (Details) - Schedule of Inventory, Current - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Schedule of Inventory, Current [Abstract]
Raw Materials	$ 66,763	$ 44,333
Work in Process	0	55,502
Finished Goods	95,520	1,552
Total Inventory, net	$ 162,283	$ 101,387

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation	$ 2,528	$ 1,137

Property and Equipment (Detai_2

Property and Equipment (Details) - Property, Plant and Equipment	3 Months Ended
	Mar. 31, 2020
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	6 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	3 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	7 years

Property and Equipment (Detai_3

Property and Equipment (Details) - Property, Plant and Equipment - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Accumulated Depreciation	$ (44,675)	$ (42,147)
Total	111,055	93,055
Tools, Dies and Molds [Member]
Property, Plant and Equipment [Line Items]
Property, plant and Equipment, gross	132,513	132,513
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and Equipment, gross	20,528	0
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and Equipment, gross	$ 2,689	$ 2,689

Patents (Details)

Patents (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization	$ 452	$ 834

Patents (Details) - Schedule of

Patents (Details) - Schedule of Finite-Lived Intangible Assets - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Schedule of Finite-Lived Intangible Assets [Abstract]
Total Patents	$ 77,722	$ 77,722
Accumulated Amortization	(70,940)	(70,488)
Patent costs, net	$ 6,782	$ 7,234

Patents (Details) - Schedule _2

Patents (Details) - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Abstract]
2020 – remaining nine months	$ 1,357
2021	1,809
2022	1,809
2023	1,807
2024 and thereafter	0
Total	$ 6,782	$ 7,234

Patents (Details) - Schedule _3

Patents (Details) - Schedule of Indefinite-Lived Intangible Assets - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Schedule of Indefinite-Lived Intangible Assets [Abstract]
Total Trademarks	$ 54,474	$ 49,867
Accumulated Amortization	0	0
Total Trademarks	$ 54,474	$ 49,867

Leases (Details)

Leases (Details)	3 Months Ended
	Mar. 31, 2020
Disclosure Text Block [Abstract]
Lessee, Operating Lease, Term of Contract	5 years
Lessee, Operating Lease, Renewal Term	3 years
Applicable Federal Rate	3.00%

Leases (Details) - Lessee, Oper

Leases (Details) - Lessee, Operating Lease, Disclosure - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Assets
ROU assets - operating lease	$ 96,354	$ 101,883
Total ROU assets	96,354
Liabilities
Current operating lease liability	21,704	21,365
Long-term operating lease liability	75,992	$ 81,494
Total lease liabilities	$ 97,696

Leases (Details) - Lease, Cost

Leases (Details) - Lease, Cost	3 Months Ended
	Mar. 31, 2020USD ($)
Lease, Cost [Abstract]
Operating lease costs	$ 6,288
Total rent expense	$ 6,288

Leases (Details) - Lessee, Op_2

Leases (Details) - Lessee, Operating Lease, Liability, Maturity - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Lessee, Operating Lease, Liability, Maturity [Abstract]
2020 - remaining nine months	$ 18,239
2021	24,886
2022	25,633
2023	26,402
2024	8,886
2025 and beyond	0
Total future minimum lease payments	104,046
Less: Interest	6,350
Total operating lease liabilities	97,696
Current operating lease liability	21,704	$ 21,365
Long-term operating lease liability	$ 75,992	$ 81,494

Notes Payable (Details)

Notes Payable (Details)	May 31, 2018USD ($)$ / shares	Aug. 31, 2016USD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)shares	Dec. 31, 2019USD ($)
Converted Account Payable to Promissory Note [Member]
Notes Payable (Details) [Line Items]
Debt Instrument, Face Amount		$ 131,722
Debt Instrument, Term		3 years
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Interest Expense, Debt				$ 489
Interest Payable, Current			$ 0
The 2018 Convertible Notes [Member]
Notes Payable (Details) [Line Items]
Debt Instrument, Face Amount	$ 895,000
Debt Instrument, Interest Rate, Stated Percentage	9.00%
Interest Expense, Debt			9,424	14,870
Interest Payable, Current			89,518			$ 80,094
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares	$ 0.20
Number of Note Holders					3
Debt Conversion, Original Debt, Amount				$ 37,377	$ 200,000
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | shares				268,615	1,055,415
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 895,000
Amortization of Debt Discount (Premium)			36,487	$ 93,237
Convertible Debt			371,695			420,000
Debt Instrument, Unamortized Discount			137,823			191,461
The 2018 Convertible Notes [Member] | Principal [Member]
Notes Payable (Details) [Line Items]
Debt Conversion, Original Debt, Amount				50,000
Convertible Debt			$ 420,000			$ 325,784
The 2018 Convertible Notes [Member] | Accrued Interest [Member]
Notes Payable (Details) [Line Items]
Debt Conversion, Original Debt, Amount				$ 3,723
The 2018 Convertible Notes, Due January 30, 2021 [Member]
Notes Payable (Details) [Line Items]
Convertible Notes Payable	550,000
The 2018 Convertible Notes, Due March 31, 2021 [Member]
Notes Payable (Details) [Line Items]
Convertible Notes Payable	$ 345,000

Notes Payable and Other Relat_3

Notes Payable and Other Related Party Transactions (Details) - USD ($)	Aug. 07, 2019	Mar. 31, 2020	Feb. 29, 2020	Feb. 28, 2019	Jan. 31, 2019	May 31, 2018	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2011	Nov. 30, 2011	Apr. 30, 2011
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Debt Conversion, Original Debt, Amount				$ 53,723			$ 0	$ 53,723
Interest Expense, Related Party							897	1,751
Repayments of Related Party Debt							0	62,743
Stock Issued During Period, Shares, Issued for Services (in Shares)		50,000	50,000		60,000
Stock Issued During Period, Value, Issued for Services		$ 11,500	$ 11,500		$ 26,600
Accounts Payable, Related Parties		$ 0					0	13,018
The 2018 Convertible Notes [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Debt Instrument, Face Amount						$ 895,000
Debt Instrument, Interest Rate, Stated Percentage						9.00%
Debt Conversion, Original Debt, Amount								37,377	$ 200,000
Debt Instrument, Convertible, Conversion Price (in Dollars per share)						$ 0.20
Immediate Family Member of Management or Principal Owner [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Debt Instrument, Face Amount													$ 50,000
Debt Instrument, Interest Rate, Stated Percentage	10.00%												10.00%
Debt Conversion, Original Debt, Amount											$ 25,000
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	$ 0.0065										$ 0.03
Interest Expense, Related Party							0	616
Repayments of Related Party Debt	$ 65,197
Immediate Family Member of Management or Principal Owner [Member] | 2011 Notes [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Debt Instrument, Face Amount												$ 10,000
Debt Instrument, Interest Rate, Stated Percentage												10.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share)												$ 0.01
Interest Expense, Related Party							0	247
Immediate Family Member of Management or Principal Owner [Member] | The 2018 Convertible Notes [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Debt Instrument, Face Amount						$ 40,000
Debt Instrument, Interest Rate, Stated Percentage						9.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share)						$ 0.20
Interest Expense, Related Party							3,431	3,393
Immediate Family Member of Management or Principal Owner [Member] | Building [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Operating Leases, Rent Expense							0	1,800
Related Party Transaction, Expenses from Transactions with Related Party							$ 0	$ 778
Charles Mulrey and Family [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)						150,000
Sale of Stock, Price Per Share (in Dollars per share)						$ 0.20
Proceeds from Issuance of Common Stock						$ 30,000
One of Directors, Dr. Kevin Doody [Member] | Restricted Stock [Member]
Notes Payable and Other Related Party Transactions (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services (in Shares)										3,000,000
Stock Issued During Period, Value, Issued for Services										$ 1,530,000

Notes Payable and Other Relat_4

Notes Payable and Other Related Party Transactions (Details) - Schedule of Related Party Transactions - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Related Party Loans	$ 33,152	$ 28,824
Less discount	(13,720)	(17,151)
The 2018 Convertible Notes [Member]
Related Party Transaction [Line Items]
Less discount	(137,823)	(191,461)
Immediate Family Member of Management or Principal Owner [Member] | The 2018 Convertible Notes [Member]
Related Party Transaction [Line Items]
Related Party Loans	$ 46,872	$ 45,975

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - USD ($)	1 Months Ended					3 Months Ended
	Mar. 31, 2020	Feb. 29, 2020	Jan. 31, 2020	Feb. 28, 2019	Jan. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Stockholders’ Equity (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services	50,000	50,000			60,000
Stock Issued During Period, Value, Issued for Services (in Dollars)	$ 11,500	$ 11,500			$ 26,600
Debt Conversion, Converted Instrument, Shares Issued				268,615
Debt Conversion, Original Debt, Amount (in Dollars)				$ 53,723		$ 0	$ 53,723
2019 Plan [Member]
Stockholders’ Equity (Details) [Line Items]
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture		99,112	1,000,000
Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture (in Dollars)		$ 25,000	$ 221,400
Stock Issued During Period, Shares, Issued for Services		60,000
Stock Issued During Period, Value, Issued for Services (in Dollars)		$ 15,000
Employee [Member] | 2019 Plan [Member]
Stockholders’ Equity (Details) [Line Items]
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture		100,000
Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture (in Dollars)		$ 24,750
Director [Member] | 2019 Plan [Member]
Stockholders’ Equity (Details) [Line Items]
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture		99,112

Stock Options and Warrants (Det

Stock Options and Warrants (Details) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Oct. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Stock Options and Warrants (Details) [Line Items]
Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term		3 years 219 days		2 years 219 days
Share-based Payment Arrangement, Noncash Expense (in Dollars)		$ 381,475	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares)		1,398,224
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in Shares)		1,157,889
Restricted Stock [Member]
Stock Options and Warrants (Details) [Line Items]
Share-based Payment Arrangement, Noncash Expense (in Dollars)		$ 265,963
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares)		1,398,224
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in Shares)		1,157,889
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount (in Dollars)		$ 154,178
2019 Plan [Member]
Stock Options and Warrants (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)	16,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)		$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term		3 years 219 days
Share-based Payment Arrangement, Noncash Expense (in Dollars)		$ 381,475
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition		1794251 years
2019 Plan [Member] | Minimum [Member]
Stock Options and Warrants (Details) [Line Items]
Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term	3 years
2019 Plan [Member] | Maximum [Member]
Stock Options and Warrants (Details) [Line Items]
Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term	10 years

Stock Options and Warrants (D_2

Stock Options and Warrants (Details) - Schedule of Stock Options Roll Forward - USD ($)		3 Months Ended
		Mar. 31, 2020	Dec. 31, 2019
Stock Options and Warrants (Details) - Schedule of Stock Options Roll Forward [Line Items]
Balance, Options Outstanding, Number of Shares (in Shares)		8,320,587
Balance, Options Outstanding, Weighted Average Exercise Price		$ 0.25	$ 0.26
Balance, Options Outstanding, Aggregate Intrinsic Value (in Dollars)	[1]	$ 0
Balance, Options Exercisable, Aggregate Intrinsic Value (in Dollars)	[1]	$ 0	$ 0
Balance, Options Exercisable, Number of Shares (in Shares)		360,176
Balance, Options Exercisable, Weighted Average Exercise Price		$ 0.23	$ 0.26
Vested, Options Exercisable, Number of Shares (in Shares)		1,998,544
Vested, Options Exercisable, Weighted Average Exercise Price		$ 0.23
Granted, Options Outstanding (in Shares)		5,275,560
Granted, Options Outstanding		$ 0.22
Balance, Options Outstanding, Number of Shares (in Shares)		13,596,147
Balance, Options Exercisable, Number of Shares (in Shares)		2,358,720
Minimum [Member]
Stock Options and Warrants (Details) - Schedule of Stock Options Roll Forward [Line Items]
Balance, Options Outstanding, Price per Share Range		$ 0.21	0.26
Granted, Options Outstanding		0.21
Maximum [Member]
Stock Options and Warrants (Details) - Schedule of Stock Options Roll Forward [Line Items]
Balance, Options Outstanding, Price per Share Range		0.29	$ 0.29
Granted, Options Outstanding		$ 0.26
[1]	The intrinsic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the option of in-the-money options only.

Stock Options and Warrants (D_3

Stock Options and Warrants (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Stock Options and Warrants (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate range		0.00%
Expected life of option-years		0 years
Expected stock price volatility		0.00%
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Stock Options and Warrants (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate range	0.48%
Expected life of option-years	5 years 73 days
Expected stock price volatility	110.80%
Maximum [Member]
Stock Options and Warrants (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate range	1.65%
Expected life of option-years	5 years 281 days
Expected stock price volatility	128.00%

Stock Options and Warrants (D_4

Stock Options and Warrants (Details) - Share-based Payment Arrangement, Option, Exercise Price Range - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (in Shares)	13,596,147	8,320,587	8,320,587
Weighted Average Remaining Life in Years	3 years 219 days	2 years 219 days
Weighted Average Exercise Price	$ 0.25	$ 0.26
Options Exercisable (in Shares)	2,358,720	360,176	360,176
Weighted Average Exercise Price of Options Exercisable	$ 0.23	$ 0.26
Total Intrinsic Value of Options Exercised (in Dollars)	$ 0
Total Fair Value of Options Vested (in Dollars)	$ 378,537	$ 69,787
Minimum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	$ 0.21	$ 0.26
Maximum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	$ 0.29	$ 0.29

Stock Options and Warrants (D_5

Stock Options and Warrants (Details) - Nonvested Restricted Stock Shares Activity - USD ($)	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Nonvested Restricted Stock Shares Activity [Abstract]
Balance, Number of Unvested Shares	573,669	333,334
Balance, Weighted Average Grant Date Fair Value	$ 0.27	$ 0.30
Balance, Aggregate Value of Unvested Shares	$ 154,178	$ 100,000
Granted, Number of Unvested Shares	1,398,224
Granted, Weighted Average Grant Date Fair Value	$ 0.23
Granted, Aggregate Value of Unvested Shares	$ 320,140
Vested, Number of Unvested Shares	(1,157,889)
Vested, Weighted Average Grant Date Fair Value	$ 0.23
Vested, Aggregate Value of Unvested Shares	$ (265,963)
Forfeitures, Number of Unvested Shares	0
Forfeitures, Weighted Average Grant Date Fair Value	$ 0
Forfeitures, Aggregate Value of Unvested Shares	$ 0

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Tax Expense (Benefit)	$ 0	$ 0
Effective Income Tax Rate Reconciliation, Percent	0.00%		0.00%

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Jan. 17, 2020	Oct. 10, 2019	Aug. 07, 2019	Jan. 17, 2017	Jan. 15, 2017	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2011	Apr. 30, 2011
Commitments and Contingencies (Details) [Line Items]
Repayments of Related Party Debt						$ 0	$ 62,743
Salary and Wage, Officer, Excluding Cost of Good and Service Sold		$ 260,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price						$ 0.22
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures						5,275,560
Immediate Family Member of Management or Principal Owner [Member]
Commitments and Contingencies (Details) [Line Items]
Repayments of Related Party Debt			$ 65,197
Debt Instrument, Term			30 days
Debt Instrument, Interest Rate, Stated Percentage			10.00%						10.00%
Debt Instrument, Convertible, Terms of Conversion Feature			Investors had the option to convert any unpaid principal and accrued interest into shares of Company’s common stock original conversion prices of $.03 and $.01, respectively, subject to adjustments upon the Company’s issuances of stock at prices less than the original conversion prices during the 24-months after issuance of each note (i.e. currently $0.0065)
Debt Instrument, Convertible, Conversion Price			$ 0.0065					$ 0.03
Deferred Compensation Arrangement with Individual, Description		Mr. Shum is eligible to earn bonus compensation of up to $75,000 bonus upon a successful up-listing to the NASDAQ exchange. All other bonus amounts will be determined by the Board of Directors, in their sole discretion.
Shares Issued, Shares, Share-based Payment Arrangement, Forfeited		400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		6,483,171
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 0.255
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years
Chief Operating Officer [Member]
Commitments and Contingencies (Details) [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 0.21378
Employment Agreement, Annual Base Salary					$ 220,000
Employment Agreement, Bonus Decription					target annual incentive bonus of up to 50% of his base salary if the Company achieves goals and objectives determined by the board of directors
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture				1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures				4,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	One quarter of the Option vested upon grant, and the remainder vests in monthly increments over a period of two years from the date of grant.

Contracts with Customers (Detai

Contracts with Customers (Details) - USD ($)	Jan. 16, 2020	Sep. 20, 2019	Sep. 19, 2019	Sep. 11, 2019	Jan. 14, 2019	Dec. 31, 2019	Mar. 31, 2020
Contracts with Customers (Details) [Line Items]
Proceeds from License Fees Received					$ 5,000,000	$ 5,000,000
Potential Licensing Fee					$ 3,000,000
Deferred Revenue						$ 4,477,261	$ 4,107,143
Joint Venture, Ownership Percentage	50.00%
Sudan, Uganda, and Ethiopia [Member]
Contracts with Customers (Details) [Line Items]
Distribution Agreement, Term		1 year
NIGERIA
Contracts with Customers (Details) [Line Items]
Distribution Agreement, Term				1 year
JORDAN
Contracts with Customers (Details) [Line Items]
Distribution Agreement, Term			1 year

Contracts with Customers (Det_2

Contracts with Customers (Details) - Disaggregation of Revenue - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue [Line Items]
Revenue	$ 258,571	$ 189,432
Domestic Physicians [Member]
Disaggregation of Revenue [Line Items]
Revenue	80,000	10,860
Domestic Licensing & Distribution Fee [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 178,571	$ 178,572

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)	May 15, 2020	May 31, 2020
Subsequent Events (Details) [Line Items]
Number of Units	5,851,900
Unit, Exercise Price	$ 0.25
Unit, Description	with each Unit exercisable for (A) one share of our common stock and (B) a 5-year warrant (the “Warrants”) to purchase one share of our common stock at an exercise price of $0.30
Warrants and Rights Outstanding, Term	5 years
Secured Convertible Debenture, Units	Each purchaser of a Note will be issued a 5-year Purchase Option to purchase 2.78 Units for each dollar of Notes purchased
Proceeds from Debt, Net of Issuance Costs	$ 1,961,360
Payments of Debt Issuance Costs	$ 143,640
Debt Instrument, Payment Terms	interest on such Notes accrues at a rates of ten percent (10%) per annum and is payable either in cash or in shares of our common stock at the conversion price in the Note on each of the six and twelve month anniversary of the issuance date and on the maturity date of November 15, 2021
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Debt Instrument, Maturity Date	Nov. 15, 2021
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		230,000
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture		$ 48,730
Principal [Member]
Subsequent Events (Details) [Line Items]
Convertible Debt	$ 2,105,000